GERMANTOWN, Md., Oct. 27, 2021 /PRNewswire/ -- Precigen,
Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing
in the development of innovative gene and cell therapies to improve
the lives of patients, today announced that the Company will host a
virtual event on Thursday, November 4,
2021 at 11:00 AM ET to provide
an update on the progress for its clinical pipeline.
The event will showcase data from several of the Company's most
advanced clinical programs, such as PRGN-3005
UltraCAR-T®, PRGN-3006
UltraCAR-T®, PRGN-2009 OTS AdenoVerse™
Immunotherapy and PRGN-2012 OTS AdenoVerse™ Immunotherapy. Precigen
executives and key opinion leaders will participate in the event,
including:
- Helen Sabzevari, PhD, President
and CEO of Precigen
- Mary L. (Nora) Disis, MD,
University of Washington (UW) Professor
of Medicine, Director of UW Center for Translational Medicine,
Professor in the Clinical Research Division at Fred Hutch and a
lead investigator for the PRGN-3005 clinical study
- David Sallman, MD, Assistant
Member in the Department of Malignant Hematology at the H. Lee
Moffitt Cancer Center & Research Institute and a lead
investigator for the PRGN-3006 clinical study
- James L. Gulley, MD, PhD, Branch
Chief and Director of the Medical Oncology Service at the National
Institutes of Health (NIH) and a lead investigator for the
PRGN-2009 clinical study
- Clint T. Allen, MD, Principal
Investigator with the Section on Translational Tumor Immunology at
the NIH and a lead investigator for the PRGN-2012 clinical
study
Participants may register and access the live webcast through
Precigen's investor relations website in the Press &
Events section. An archived recording will be posted to the
investor relations website following the event.
Precigen: Advancing Medicine with Precision™
Precigen
(Nasdaq: PGEN) is a dedicated discovery and clinical stage
biopharmaceutical company advancing the next generation of gene and
cell therapies using precision technology to target urgent and
intractable diseases in our core therapeutic areas of
immuno-oncology, autoimmune disorders, and infectious diseases. Our
technologies enable us to find innovative solutions for affordable
biotherapeutics in a controlled manner. Precigen operates as an
innovation engine progressing a preclinical and clinical pipeline
of well-differentiated unique therapies toward clinical
proof-of-concept and commercialization. For more information about
Precigen, visit www.precigen.com or follow us on Twitter @Precigen
and LinkedIn.
Trademarks
Precigen, UltraCAR-T, AdenoVerse and
Advancing Medicine with Precision are trademarks of Precigen and/or
its affiliates. Other names may be trademarks of their respective
owners.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release
are forward-looking statements. These forward-looking statements
are based upon the Company's current expectations and projections
about future events and generally relate to plans, objectives, and
expectations for the development of the Company's business,
including the timing and progress of preclinical studies, clinical
trials, discovery programs and related milestones, the promise of
the Company's portfolio of therapies, and in particular its CAR-T
and AdenoVerse therapies. Although management believes that the
plans and objectives reflected in or suggested by these
forward-looking statements are reasonable, all forward-looking
statements involve risks and uncertainties, including the
possibility that the timeline for the Company's clinical trials
might be impacted by the COVID-19 pandemic, and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release. The Company has no
obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. For further information on potential risks
and uncertainties, and other important factors, any of which could
cause the Company's actual results to differ from those contained
in the forward-looking statements, see the section entitled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K
and subsequent reports filed with the Securities and Exchange
Commission.
For more information, contact:
Investor
Contact: Steven
Harasym Vice President,
Investor Relations Tel: +1
(301) 556-9850 investors@precigen.com
|
Media
Contacts: Donelle M.
Gregory press@precigen.com
|
|
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-to-host-rd-update-virtual-event-on-november-4th-to-share-clinical-developments-301410331.html
SOURCE Precigen, Inc.